Publications by authors named "A Pigazzi"

Article Synopsis
  • The study aims to assess the impact of transanal total mesorectal excision (taTME) on fecal incontinence and various functional outcomes (defecatory, urinary, and sexual) in patients with rectal cancer.
  • It was found that while initial outcomes post-surgery showed a decline in fecal continence and defecatory function, patient outcomes improved significantly by 12 months after ileostomy closure, though they did not fully recover to preoperative levels.
  • Urinary function remained stable throughout the study, but both female and male sexual functions declined without signs of recovery in the follow-up period.
View Article and Find Full Text PDF

Introduction: We have shown in a Phase I trial that immediate adjuvant chemotherapy (IAC) during surgical resection and immediately postoperative is safe and feasible in patients with colon cancer (CC). IAC avoids delays in adjuvant treatment and has the potential to improve survival and quality of life. We aim to determine patients and providers attitudes toward this novel multidisciplinary treatment approach.

View Article and Find Full Text PDF

Background: Incisional hernia (IH) is a known complication after colorectal surgery. Despite advances in minimally invasive surgery, colorectal surgery still requires extraction sites for specimen retrieval, increasing the likelihood of postoperative IH development. The objective of this study is to determine the effect of specimen extraction site on the rate of IH after minimally invasive right-sided colectomy for patients with available imaging.

View Article and Find Full Text PDF

Background: Monoclonal antibody drugs are widely used, highly marketed, expensive compounds. Relationships between these drug manufacturers and physicians may increase the potential for bias in relevant studies.

Objective: The aim of this study is to determine the rate of disclosures among physicians receiving compensations for monoclonal antibody drugs (MAbDs).

View Article and Find Full Text PDF

In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy has shown limited efficacy. Herein, we report exceptional responses observed with neoadjuvant botensilimab (BOT), an Fc-enhanced next-generation anti-CTLA-4 antibody, alongside balstilimab (BAL; an anti-PD-1 antibody) in two patients with pMMR/MSS colon and rectal cancer.

View Article and Find Full Text PDF